Alaunos Therapeutics (TCRT) FDA Approvals $2.42 +0.05 (+2.11%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.47 +0.05 (+2.11%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Alaunos Therapeutics' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Alaunos Therapeutics (TCRT). Over the past two years, Alaunos Therapeutics has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as ALN1003. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. ALN1003 FDA Regulatory Events ALN1003 is a drug developed by Alaunos Therapeutics for the following indication: Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Preclinical Data - May 18,2026Preclinical Data Drug: ALN1003Announced Date: May 18, 2026Indication: Non-Hormonal Oral Treatment for Obesity and Related Metabolic DisordersAnnouncementAlaunos Therapeutics, Inc. announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's investigational oral metabolic therapeutic candidate.AI SummaryAlaunos Therapeutics said its updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies support further development of ALN1003, an oral metabolic drug candidate. The results suggest the compound may affect several key drivers of metabolic dysfunction, including insulin resistance, fat tissue signaling, and liver lipid metabolism. The company said ALN1003 could have potential use in metabolic syndrome and related disorders. To build on these findings, Alaunos plans more preclinical testing focused on finding the best dose, understanding exposure-response relationships, expanding metabolic measurements, and studying liver damage and the biological pathways involved. The company also noted that it has limited cash and expects its current runway to last into the second quarter of 2026, so it plans to seek additional financing to continue its obesity and metabolic disorders program.Read AnnouncementData - March 2,2026Data Drug: ALN1003Announced Date: March 2, 2026Indication: Non-Hormonal Oral Treatment for Obesity and Related Metabolic DisordersAnnouncementAlaunos Therapeutics, Inc. announced early data from two non-Good Laboratory Practice (non-GLP) diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's lead small-molecule drug candidate for treating obesity and related conditions, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease).AI SummaryAlaunos Therapeutics reported early, non‑GLP data from two diet‑induced obesity (DIO) mouse studies of ALN1003, its oral small‑molecule candidate for obesity and related metabolic disease. In Study 1, ALN1003-treated mice showed peak mean weight loss of –12.9% (p<0.0001) on Day 34 and –10.3% (p<0.0001) at Day 48 versus DIO controls. Treated mice ate less overall (347.5 g vs 425.0 g per cage; nominal p<0.05). Study 2 body-composition analysis showed dose-related losses driven mainly by fat but also by lean and fluid mass. At the highest dose, mice had lower blood glucose (197 vs 320 mg/dL; p<0.0001) and lower total cholesterol (162 vs 209 mg/dL; nominal p<0.05); HDL also fell (nominal p<0.05). Tolerability was generally acceptable, with transient, mild hypolocomotion after dosing in Study 1 and two slightly dehydrated high‑dose mice in Study 2. The company noted that drug‑related loss of appetite and thirst may have reduced drinking of medicated water, which can confound weight‑loss attribution. These early results will guide ongoing preclinical work and CMC development.Read Announcement Alaunos Therapeutics FDA Events - Frequently Asked Questions Has Alaunos Therapeutics received FDA approval? As of now, Alaunos Therapeutics (TCRT) has not received any FDA approvals for its therapy in the last two years. What drugs has Alaunos Therapeutics submitted to the FDA? In the past two years, Alaunos Therapeutics (TCRT) has reported FDA regulatory activity for ALN1003. What is the most recent FDA event for Alaunos Therapeutics? The most recent FDA-related event for Alaunos Therapeutics occurred on May 18, 2026, involving ALN1003. The update was categorized as "Preclinical Data," with the company reporting: "Alaunos Therapeutics, Inc. announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's investigational oral metabolic therapeutic candidate." What conditions do Alaunos Therapeutics' current drugs treat? Currently, Alaunos Therapeutics has one therapy (ALN1003) targeting the following condition: Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events AC Immune FDA EventsAgios Pharmaceuticals FDA EventsAssembly Biosciences FDA EventsBriacell Therap FDA EventsBioLineRx FDA EventsFibroBiologics FDA EventsGilead Sciences FDA EventsOncolytics Biotech FDA EventsRegeneron Pharmaceuticals FDA EventsAbbVie FDA EventsMerck & Co., Inc. FDA EventsAgenus FDA EventsAdagio Medical FDA EventsAktis Oncology FDA EventsAkari Therapeutics FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Oncobiologics FDA Events Marker Therapeutics FDA Events Allarity Therapeutics FDA Events Novogen FDA Events Celularity FDA Events VYNE Therapeutics FDA Events Quantum Biopharma FDA Events Exicure FDA Events Quince Therapeutics FDA Events Lipocine FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:TCRT last updated on 5/18/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredA 25,000% opportunityAngel investor Jason Calacanis - who made a fortune on an early Uber stake - says Elon Musk's latest project c...The Oxford Club | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredOne coin wired into Elon's visionSpaceX just filed its IPO paperwork. And buried inside that filing was something that should change how every ...Crypto 101 Media | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Preclinical Data - May 18,2026Preclinical Data Drug: ALN1003Announced Date: May 18, 2026Indication: Non-Hormonal Oral Treatment for Obesity and Related Metabolic DisordersAnnouncementAlaunos Therapeutics, Inc. announced updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's investigational oral metabolic therapeutic candidate.AI SummaryAlaunos Therapeutics said its updated preclinical data from non-GLP diet-induced obesity (DIO) mouse studies support further development of ALN1003, an oral metabolic drug candidate. The results suggest the compound may affect several key drivers of metabolic dysfunction, including insulin resistance, fat tissue signaling, and liver lipid metabolism. The company said ALN1003 could have potential use in metabolic syndrome and related disorders. To build on these findings, Alaunos plans more preclinical testing focused on finding the best dose, understanding exposure-response relationships, expanding metabolic measurements, and studying liver damage and the biological pathways involved. The company also noted that it has limited cash and expects its current runway to last into the second quarter of 2026, so it plans to seek additional financing to continue its obesity and metabolic disorders program.Read Announcement
Data - March 2,2026Data Drug: ALN1003Announced Date: March 2, 2026Indication: Non-Hormonal Oral Treatment for Obesity and Related Metabolic DisordersAnnouncementAlaunos Therapeutics, Inc. announced early data from two non-Good Laboratory Practice (non-GLP) diet-induced obesity (DIO) mouse studies evaluating ALN1003, the Company's lead small-molecule drug candidate for treating obesity and related conditions, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease).AI SummaryAlaunos Therapeutics reported early, non‑GLP data from two diet‑induced obesity (DIO) mouse studies of ALN1003, its oral small‑molecule candidate for obesity and related metabolic disease. In Study 1, ALN1003-treated mice showed peak mean weight loss of –12.9% (p<0.0001) on Day 34 and –10.3% (p<0.0001) at Day 48 versus DIO controls. Treated mice ate less overall (347.5 g vs 425.0 g per cage; nominal p<0.05). Study 2 body-composition analysis showed dose-related losses driven mainly by fat but also by lean and fluid mass. At the highest dose, mice had lower blood glucose (197 vs 320 mg/dL; p<0.0001) and lower total cholesterol (162 vs 209 mg/dL; nominal p<0.05); HDL also fell (nominal p<0.05). Tolerability was generally acceptable, with transient, mild hypolocomotion after dosing in Study 1 and two slightly dehydrated high‑dose mice in Study 2. The company noted that drug‑related loss of appetite and thirst may have reduced drinking of medicated water, which can confound weight‑loss attribution. These early results will guide ongoing preclinical work and CMC development.Read Announcement
